Shanghai Innostar Bio-Tech Co., Ltd. (688710.SH) announced that its wholly-owned subsidiary, Innostar Bio-Tech Nantong Co., Ltd., has successfully passed a GLP inspection by the National Medical Products Administration for its "Expansion Project of the High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform." The subsidiary has received the "Drug GLP Certification Certificate" issued by the NMPA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.